Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kemodoxa
- Development stage
- Unknown
- Lead developer
- Bharat Serums and Vaccines
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Kemodoxa is a liposomal formulation of doxorubicin hydrochloride developed and manufactured by Bharat Serums and Vaccines (BSV). As a cytotoxic chemotherapy agent, it functions by intercalating into DNA and inhibiting the enzyme DNA topoisomerase II, which prevents DNA replication and transcription in rapidly dividing cancer cells. The liposomal drug delivery system (NDDS) is designed to modify the drug's pharmacokinetic profile, extending circulation time and potentially reducing systemic toxicities, such as cardiotoxicity, compared to conventional doxorubicin formulations. Kemodoxa is available as a non-pegylated, long-circulating liposomal composition for intravenous administration and is indicated for various oncologic conditions.
- Brand names
- Kemodoxa
- Other names
- liposomal doxorubicindoxorubicin hydrochloride liposome injection
Beyond the preview
Go deeper on Kemodoxa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kemodoxa.